The United Laboratories International Holdings Ltd. is an investment company, which engages in manufacturing and selling medicine products. The company employs 17,400 full-time employees The company went IPO on 2007-06-15. The firm operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.
The United Laboratories International Holdings Limited 的关键财务报表是什么?
根据最新的财务报表(Form-10K),The United Laboratories International Holdings Limited 的总资产为 $25,833,净利润为 $2,659
ULIHF 的关键财务比率是什么?
The United Laboratories International Holdings Limited 的流动比率是 2.25,净利 margin 为 19.32,每股销售为 $7.57。
The United Laboratories International Holdings Limited 的收入按细分市场或地理位置如何划分?
The United Laboratories International Holdings Limited 最大收入来源是 Bulk Medicine,在最近的收益报告中收入为 6,909,415,147。就地区而言, China, including Hong Kong 是 The United Laboratories International Holdings Limited 的主要市场,收入为 12,051,782,799。
The United Laboratories International Holdings Limited 是否盈利?
是的,根据最新的财务报表,The United Laboratories International Holdings Limited 的净利润为 $2,659
The United Laboratories International Holdings Limited 有负债吗?
是的,The United Laboratories International Holdings Limited 的负债为 11,444
The United Laboratories International Holdings Limited 的流通股有多少?
The United Laboratories International Holdings Limited 的总流通股为 1,817.02